Key result
New selective coagulation factor inhibitors offer improved efficacy, safety, and convenience over traditional anticoagulants.
Why the study?
Current anticoagulants such as unfractionated and low-molecular-weight heparins and vitamin K antagonists have limitations including narrow therapeutic windows and need for monitoring.
Design
Review of clinical trials and development status
Authors
Loading...
May encourage targeted anticoagulant development; leaves open confirmation of benefits in prospective trials.
Newer targeted anticoagulants offer potential advantages over traditional therapies like VKAs and heparins, including predictable dose-responses and no need for routine monitoring.
Kenneth Alan Bauer (2008) conducted a review in Thrombosis. New anticoagulants (fondaparinux, direct factor Xa inhibitors, direct thrombin inhibitors) vs. Existing anticoagulants (vitamin K antagonists, heparins) was evaluated. Selective inhibitors of specific coagulation factors have the potential to be more effective, safer, and easier to use than existing anticoagulants for the prevention and treatment of thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: